| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/07/2002 | WO2002017848A1 Hard capsule |
| 03/07/2002 | WO2002017713A1 Collagen/polysaccharide bilayer matrix |
| 03/07/2002 | WO2001093911A3 Macromolecular drug complexes and compositions containing the same |
| 03/07/2002 | WO2001091848A3 Medicament-loaded transdermal reservoir and method for its formation |
| 03/07/2002 | WO2001089571A3 Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives |
| 03/07/2002 | WO2001089474A3 O/w emulsion |
| 03/07/2002 | WO2001087329A8 Liquid pharmaceutical composition containing an erythropoietin derivate |
| 03/07/2002 | WO2001087232A3 Allantoin-containing skin cream |
| 03/07/2002 | WO2001085777A3 Therapeutic pore-forming peptides |
| 03/07/2002 | WO2001070274A3 Local drug delivery |
| 03/07/2002 | WO2001068122A3 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |
| 03/07/2002 | WO2001064187B1 Anaesthetic formulations |
| 03/07/2002 | WO2001059078A3 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| 03/07/2002 | WO2001056613A3 Sterile water generator |
| 03/07/2002 | WO2001055092B1 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 03/07/2002 | WO2001052896A3 Compositions with enhanced oral bioavailability |
| 03/07/2002 | WO2001051028A3 Formulations and methods for administration of pharmacologically or biologically active compounds |
| 03/07/2002 | WO2001049261A3 Stable aqueous deoxyfructosazine solution |
| 03/07/2002 | WO2001044808A3 Methods of diagnosis and treatment by binding p75/airm1 |
| 03/07/2002 | WO2001041758A3 Valnemulin formulation |
| 03/07/2002 | WO2001031006A3 Serum amyloid a isoform from colostrum |
| 03/07/2002 | WO2001028591A3 Injection vehicle for polymer-based formulations |
| 03/07/2002 | WO2001024831A3 Polymer stabilized neuropeptides |
| 03/07/2002 | WO2001021163A3 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 03/07/2002 | WO2001009165A3 ACTIVATION OF PEPTIDE PRODRUGS BY hK2 |
| 03/07/2002 | WO2000071571A8 Fap-activated anti-tumor compounds |
| 03/07/2002 | US20020028943 For lowering serum lipid, cholesterol and/or triglyceride levels; treating atherosclerosis |
| 03/07/2002 | US20020028914 Chimeric toxins for targeted therapy |
| 03/07/2002 | US20020028848 Administering orally 13-hydroxyoctadeca-9Z,11E-dienoic acid (13-HODE); anticoagulants; cardiovascular, respiratory, gastrointestinal, nervous and psyiatric disorders; autoimmune disease; antiinflammatory agents; bactericides; viricides |
| 03/07/2002 | US20020028846 Compositions and methods for amelioration of human female sexual dysfunction |
| 03/07/2002 | US20020028843 Mupirocin calcium amorphous as a microbiocide dissolved in a hydrophilic solvent, preferably, hexamethylene glycol; heat resistance; skin, ear and eye disorders; topical and nasal |
| 03/07/2002 | US20020028817 Platelet derived growth factors (PDGF); 1,2-dimethyl-6-(2-thiophene)imidazolo(5,4-g)quinoxaline preparations for example; use treating proliferative malignant and non-malignant diseases; stents |
| 03/07/2002 | US20020028789 Topical pain relief composition and carrier |
| 03/07/2002 | US20020028788 Administering estradiol in cyclodextrin adjuvant |
| 03/07/2002 | US20020028780 Antiparasitic formulations |
| 03/07/2002 | US20020028770 Bactericides |
| 03/07/2002 | US20020028769 Method for preparing zinc-oligopeptide easily absorbable by the human body |
| 03/07/2002 | US20020028766 Composition of a polypeptide and an amphiphilic compound in an ionic complex and the use thereof |
| 03/07/2002 | US20020028515 Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells |
| 03/07/2002 | US20020028276 Sugar-free products with improved characteristics |
| 03/07/2002 | US20020028252 Multifluid atomization of a dispersed system of a biologically active agent and a solvent to produce droplets; freezing the droplets; lyophilizing the frozen droplets obtain microstructures capable of being further fragmented |
| 03/07/2002 | US20020028249 Preparation of biodegradable, biocompatible microparticles containing a biolgically active agent |
| 03/07/2002 | US20020028246 Neutral support grain coated with a mixture of morphine sulfate and of a binder, such as hydroxypropylmethylcellulose; immediate-release |
| 03/07/2002 | US20020028245 Compact member, method of manufacturing and use thereof |
| 03/07/2002 | US20020028244 Biodegradable neurotoxin implant |
| 03/07/2002 | US20020028243 Protein matrix materials, devices and methods of making and using thereof |
| 03/07/2002 | US20020028239 Tablet composition |
| 03/07/2002 | US20020028238 Orally administration to provide a blood plasma concentration profile of celecoxib of at least about 250 mg/ml in not more than about 30 minutes |
| 03/07/2002 | US20020028236 Erythropoietin or derivatives that cause bone marrow cells to increase production of reticulocytes and erythrocytes; hydrogenated lecithin that may be hydrogenated; cholesterol or a derivative; phosphate buffer |
| 03/07/2002 | US20020028235 Dermal penetration enhancer is a safe skin-tolerant ester sunscreen. |
| 03/07/2002 | US20020028234 Especially medicaments containing verapamil; a lecithin/isopropyl myristate solution; butylated hydroxy toluene; pluronic F127; an antioxidant agent suspended in a carrier |
| 03/07/2002 | US20020028227 Use for cosmetic and dermatological indications, reducing and soothing mucosa and skin erythema, inflammation or reaction caused by internal or external factors, wound healing, etc. |
| 03/07/2002 | US20020028219 Novel liposome complexes for increased systemic delivery |
| 03/07/2002 | US20020028216 Controlled release implantable drug delivery system composed of a plurality of botulinum toxin-incorporating polymeric microspheres. |
| 03/07/2002 | US20020028215 Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same |
| 03/07/2002 | US20020028212 Recombinant viruses coding for a glutamate decarboxylase (gad) activity |
| 03/07/2002 | US20020028201 Element A, which is a plastic with a group derived from a carboxy acid (e.g., an acrylate polymer), is hydrogen bonded to an element B (e.g., polyalkylene glycol; coupling physiologically and/or pharmacologically active substances |
| 03/07/2002 | US20020028189 Biocompatible macromers |
| 03/07/2002 | US20020028183 Medicaments |
| 03/07/2002 | US20020028181 Polyacid/polyalkylene oxide foams and gels and methods for their delivery |
| 03/07/2002 | US20020026886 Useful for coloring of food products and pharmaceuticals do not migrate in products and they are acid stable; are useful in coating formulations for tablets and dragees |
| 03/07/2002 | DE10040610A1 Flavonhaltige Pflanzenextraktlösungen mit verbesserter Lager- und Hitzestabilität Flavonhaltige plant extract solutions with improved storage and heat stability |
| 03/07/2002 | CA2746787A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | CA2497686A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | CA2457162A1 Electroprocessed fibrin-based matrices and tissues |
| 03/07/2002 | CA2425367A1 Oct formulations |
| 03/07/2002 | CA2420897A1 Chemoprotectant for gastric toxicity |
| 03/07/2002 | CA2420804A1 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 03/07/2002 | CA2420765A1 Anti-angiogenic peptides |
| 03/07/2002 | CA2420652A1 Vertebrate intestinal protein which absorbs cholesterol, and the use of this protein for identifying inhibitors of intestinal cholesterol transport |
| 03/07/2002 | CA2420600A1 Pectin film compositions |
| 03/07/2002 | CA2420535A1 Sustained release formulations for growth hormone secretagogues |
| 03/07/2002 | CA2419935A1 Collagen/polysaccharide bilayer matrix |
| 03/07/2002 | CA2419661A1 Neutrokine-alpha and neutrokine-alpha splice variant |
| 03/07/2002 | CA2419606A1 Lung surfactant compositions with dynamic swelling behaviour |
| 03/07/2002 | CA2419249A1 Water-dispersible encapsulated sterols |
| 03/07/2002 | CA2418038A1 Paroxetine compositions and processes for making the same |
| 03/06/2002 | EP1184034A2 Oral drug composition containing a verapamil derivative as a drug-absorption promotor |
| 03/06/2002 | EP1184033A1 Pectin film compositions |
| 03/06/2002 | EP1183954A1 Fading inhibitors |
| 03/06/2002 | EP1183538A1 Cyclodextrin polymers for use as drug carriers |
| 03/06/2002 | EP1183302A1 Controlled release polyacrylic acid granules and a process for preparing the same |
| 03/06/2002 | EP1183298A1 Cross-linked polymers that contain condensed alkaline amino acids and method for producing said polymers |
| 03/06/2002 | EP1183275A2 Combined approach to treatment of cancer with hcg vaccines |
| 03/06/2002 | EP1183271A1 Polymer conjugates of hedgehog proteins and uses |
| 03/06/2002 | EP1183270A2 Novel organic anion transport proteins |
| 03/06/2002 | EP1183230A1 Valency platform molecules comprising aminooxy groups |
| 03/06/2002 | EP1183228A2 Esters of l-carnitine or alkanoyl l-carnitines |
| 03/06/2002 | EP1183100A1 Mineral-salt based substantially or totally hydrosoluble composition, formulation containing said composition and production thereof |
| 03/06/2002 | EP1183050A2 Method for producing an injectable medicament preparation |
| 03/06/2002 | EP1183049A2 Modification of biological elements |
| 03/06/2002 | EP1183047A2 Pharmaceutical preparation |
| 03/06/2002 | EP1183041A2 Ligand for cd7, and methods for use thereof |
| 03/06/2002 | EP1183029A2 Pharmaceutical preparation containing the active substance diamorphine and its utilization in a method for treating opiate addiction |
| 03/06/2002 | EP1183027A1 Pharmaceutical formulations and methods comprising intranasal morphine |
| 03/06/2002 | EP1183026A2 Improved pharmaceutical formulations |
| 03/06/2002 | EP1183023A1 Use of verapamil and verapamil derivatives for producing medicaments with an inhibiting effect on beta-glucuronidase in human tissue |
| 03/06/2002 | EP1183022A1 Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
| 03/06/2002 | EP1183017A1 Novel formulations comprising lipid-regulating agents |
| 03/06/2002 | EP1183016A1 Stereocomplex hydrogels |